"" Ralph Moss—Cancer Consultant: LOWER-DOSE IMMUNE DRUGS AS EFFECTIVE AS HIGHER DOSES

Sunday, October 7, 2018

LOWER-DOSE IMMUNE DRUGS AS EFFECTIVE AS HIGHER DOSES


Kleef clinic, Vienna, Austria

Many of my phone consultees are surprised to hear me say that lower doses of immune checkpoint inhibitor (ICI) drugs are often as effective as the more typical higher doses, with far less toxicity.

Won’t a lower-dose regimen, they wonder, be less effective than the high-dose regimens recommended by the US Food and Drug Administration (FDA) and the drug manufacturers? Well, apparently not. This question was studied in an analysis of clinical trial, which was presented at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO). Here are the conclusions from the University of Texas M.D. Anderson Cancer Center, Houston (home institution of the co-discoverer of immune checkpoint inhibitors):
“Despite a dose-dependent increase in irAE [immune-related adverse events, ed.], we identify no improvement in PFS [progression-free survival, ed.], OS [overall survival, ed.], or DCR [disease control rate, ed.] with escalating doses of ICI [immune checkpoint inhibitors, ed.]...Lower doses may reduce toxicity and cost without compromising disease control or survival."

This is an enormously important finding, which has gotten very little attention in the media. But it is a confirmation of the approach of Ralf Kleef, MD, of Vienna, Austria, who claims excellent results using a lower-than-typical dose of ICI drugs, with far fewer serious side effects, especially when the ICIs are integrated into a holistic immune-stimulating protocol.